All studies
Ongoing, recruitingTherapeutic confirmatory (Phase III)Interventional
Clemastine fumarate as remyelinating treatment in internuclear ophthalmoparesis and multiple sclerosis (RESTORE)
At a glance
Status
Ongoing, recruiting
Phase
Therapeutic confirmatory (Phase III)
Sponsor
Amsterdam UMC Stichting
Enrolment target
80
Start
14 Aug 2024
What is this study about?
The relative change in Versional Dysconjugacy Index (VDI) of Area under the Curve (AUC) from baseline will be compared between the treatment and control group at the end of treatment (6 months) and multiple follow-up periods (12, 24 and 36 months)
Who may be eligible?
Age 18 Years to any · Sex: All
Locations (1)
- —Netherlands
How to find out more
Always speak to your GP or specialist before deciding to take part in a study.
Discussion
Community discussion
Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.